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Abstract: Pseudomembranous candidiasis is the most frequent type of 
infection by Candida spp., and Candida albicans is the most common species 
to cause it. Candidiasis can be due to other Candida species less frequently, as 
is the case of  Candida tropicalis a pathogenic species that can cause infection 
in immunocompromised patients. The aim of this case report is to describe a 
pathological condition produce by Candida tropicalis.
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INTRODUCTION.
Candidiasis refers in general terms to a superficial or deep infection of 
the skin, mucosa, or both, caused by members of the genus Candida,1 which 
can occur at any age depending on risk factors such as diabetes mellitus, 
frequent use of antibiotics, behavioral factors, and immunosuppression.2,3 
The genus Candida has several virulence factors such as adhesion factors, 
the production of biofilms, and the production and secretion of proteolytic 
enzymes, enabling it to colonize and cause infection.4,5  Oral candidiasis 
is a condition associated with the use of dental prostheses and patients 
with immunosuppression and it is mainly caused by Candida albicans, a 
Candida species with both a  yeast and hypha morphology and accounts 
for more than 80% of oral fungal isolates6  from both healthy and diseased 
persons. Other Candida species that have also being isolated from the 
oral cavity, albeit less frequently, include  Candida glabrata, Candida 
tropicalis, Candida  krusei, Candida guilliermondii, C. kefyr and Candida 
parapsilosis.6  Nonetheless,  there has been an increase in recent years in the 
number of infections produced by Candida species other than albicans in 
both systemic or oral candidiasis.6,7 
Four forms of presentation of oral candidiasis have been described: 
pseudomembranous candidiasis, acute erythematous candidiasis, 
chronic erythematous candidiasis and chronic hyperplastic candidiasis.8 
Each of these forms of candidiasis is associated with local clinical 
signs and symptoms such as the use of  extra- or intra- oral devices 
such as prosthetics, the use of steroid inhalers, a reduction of salivary 
flow, and a diet rich in carbohydrates; and a variety of predisposing 
factors such age (newborns and the elderly), endocrine disorders, 
immunosuppression or immunodeficiencies, broad spectrum antibiotic 
therapy and nutritional deficiencies.6 
Pseudomembranous candidiasis is characterized by the presence of 
superficial white plaques, especially on the palate and tongue, which are 
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easily removed from the lesion using swabs, revealing a 
bloody erythematous area.6  
This form of candidiasis is frequently associated with 
the use of steroids, and has a direct relationship with 
immunodeficiencies in HIV positive  patients and those 
with leukaemia.6,9,10 The objective of this clinical report 
is to describe a case of pseudomembranous candidiasis 
produced by Candida tropicalis.
CASE REPORT.
A 37-year-old male patient seeked medical attention 
at the odontology  clinic of the Facultad de Odontología 
of the  Universidad Católica de Santa María in Arequipa, 
Perú. During anamnesis the patient states he is completely 
healthy and during the intraoral examination, whitish 
plaques are noted throughout the mouth, mainly on the 
palate (Figure 1.A), back of the tongue (Figure 1.B) and 
cheeks (Figure 1.C and Figure 1.D). The patient mentions 
these asymptomatic plaques appear frequently for 3 to 4 
months.
The easy removal of the whitish plaques with sterile 
swabs and the consequent bloody erythematous zone leads 
to a diagnosis of pseudomembranous candidiasis. Several 
samples were immediately inoculated in CHROMagar 
Candida and incubated at 37ºC for 48 hours. Blood 
glucose and HIV tests are ordered. 
Dark blue colonies resultd from all samples on 
CHROMagar Candida (Figure 2) identifying Candida 
tropicalis.11 The laboratory blood analysis shows that the 
patient is HIV positive so he is sent to the appropriate 
hospital center for clinical management.
The patient is prescribed fluconazole 50mg once a day 
for 7 days. At a follow-up visit the patient subsequently 
informs that he is following the medical protocol prescribed 
for HIV and that the whitish plaque had disappeared 
approximately 20 days after the initial dental visit.
Figure 1. Pseudomembranous candidiasis with whitish plaques and erythematous regions.
A B
C D
A. Palate. B. Dorsum of tongue. C. Right buccal cavity. D. Left buccal cavity.
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DISCUSSION.
Candida spp. is the main cause of fungal infections 
in humans, existing not only as a commensal but as 
an opportunistic pathogen as well.7 Oral candidiasis 
is a common superficial infection in the elderly, 
immunocompromised patients, patients with dental 
prostheses and people with xerostomia, and Candida 
albicans is the most predominant species in these lesions.7 
Other species have been reported, with reports of  Candida 
glabrata, Candida tropicalis, Candida parapsilosis, Candida 
dubliniensis, Candida guillermondi, Candida krusei and 
Candida kefry isolated and cultured from oral lesions.6,7
Pseudomembranous candidiasis is the most common 
form of oral candidiasis, it is mostly asymptomatic, 
present as white plaques on the tongue, buccal mucosa, 
soft and hard palate, and oropharynx.6,8 It is mostly 
associated with Candida albicans infection, having acute 
or chronic characteristics caused by the overgrowth of 
yeast in the oral mucosa with desquamation of epithelial 
cells and accumulation of keratin, fibrin, necrotic tissue 
and the presence of fungal hyphae.8
Candida tropicalis is considered an important member 
of the Candida genus regarding epidemiology and 
virulence, as it is able to produce true hyphae and is a 
great producer of biofilms and virulence factors similar to 
those of Candida albicans.12  Candida tropicalis is normally 
present in the normal human microbiota and is associated 
with superficial and systemic infections around the world, 
being the third or fourth most isolated species in clinical 
practice13 and the second or third most isolated in Brazil 
and Latin America.14 Other factors that predispose oral 
candidiasis in immunocompetent patients are occlusion 
trauma, poor oral hygiene, xerostomia, and diabetes.15,16
Some studies have reported increased virulence of 
Candida tropicalis in immunocompromised patients;17-19 
which is in agreement with the clinical findings of this 
case report regarding HIV status. It is important  to order 
HIV testing in cases of candidiasis since its association 
with the virus is common. Likewise, it has been shown 
that Candida tropicalis is more invasive than Candida 
albicans,20 due to the neutropenia presented in patients, 
which indicates that polymorphous nuclear leukocytes 
are the first line of defense against Candida tropicalis.21
The antifungal agent fluconazole, an inhibitor of 
ergosterol synthesis, is the most used drug for the 
treatment of oral candidiasis due to its ability to absorb 
very well into mucous membranes.6 Fluconazole was an 
antifungal agent of choice in this case report. However, 
resistance to fluconazole in Candida tropicalis has been 
reported mostly in refractory candidiasis,18 so isolates 
should undergo  susceptibility testing to antifungals in 
order to resolve these issues.
 CONCLUSION.
Pseudomembranous oral candidiasis is an infection 
caused by members of the genus Candida, especially in 
Figure 2. Blue colonies of Candida tropicalis on CHROM-agar Candida from samples obtained from:
A. Palate and Tongue. B. Right and Left buccal cavities.
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immunocompromised patients, and is generally caused 
by Candida albicans; however, other non-albicans 
species of Candida, such as Candida tropicalis, can also 
cause this type of infection.
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